TY - JOUR
T1 - Venetoclax-associated interstitial pneumonitis
AU - Siddiqui, Atif Saleem
N1 - Publisher Copyright:
© 2024
PY - 2024/1
Y1 - 2024/1
N2 - Venetoclax is a selective inhibitor of the antiapoptotic protein B-cell lymphoma 2 (BCL-2). It is approved for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML) in combination with chemotherapy or hypomethylating agents. Interstitial pneumonitis due to venetoclax has not been described in the literature. We describe a case of a 79-year-old female who experienced SLL relapse and developed interstitial pneumonitis associated with venetoclax, which completely resolved after discontinuation of the medication.
AB - Venetoclax is a selective inhibitor of the antiapoptotic protein B-cell lymphoma 2 (BCL-2). It is approved for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML) in combination with chemotherapy or hypomethylating agents. Interstitial pneumonitis due to venetoclax has not been described in the literature. We describe a case of a 79-year-old female who experienced SLL relapse and developed interstitial pneumonitis associated with venetoclax, which completely resolved after discontinuation of the medication.
UR - http://www.scopus.com/inward/record.url?scp=85193449929&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85193449929&partnerID=8YFLogxK
U2 - 10.1016/j.rmcr.2024.102038
DO - 10.1016/j.rmcr.2024.102038
M3 - Article
AN - SCOPUS:85193449929
SN - 2213-0071
VL - 50
JO - Respiratory Medicine Case Reports
JF - Respiratory Medicine Case Reports
M1 - 102038
ER -